Abbott Laboratories had higher revenue in the second quarter, boosted by more sales in its diagnostics business.

The healthcare company on Thursday said its profit fell to $928 million, or 53 cents a share, in the quarter ended June 30, from $1.78 billion, or $1.01 a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were $1.31, ahead of the $1.28 anticipated by analysts, according to FactSet.

Revenue rose 13% to $12.59 billion. Analysts surveyed by FactSet forecast revenue of $12.52 billion. Comparable sales growth was 4.8%.

Sales in Abbott's diagnostics business jumped 42%. The segment was boosted in part by mid-teens growth of the cancer test Cologuard, which is benefiting from a growing base of new and repeated customers.

Medical devices sales rose 9% and established pharmaceuticals sales rose more than 8%. Revenue in the nutrition segment fell 3.1% due to lower sales volumes and the effect of recent pricing actions.

Abbott raised its outlook for full-year adjusted earnings per share to $5.45 to $5.60, up from a previous range of $5.38 to $5.58. It reaffirmed its guidance for comparable sales growth of 6.5% to 7.5%.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

July 16, 2026 07:57 ET (11:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.